The purpose of this study was to prepare ginkgolide B (GB) lyophilized powder for injection with excellent appearance and stable quality through a formulation screening and by optimizing the freeze-drying process. Cremophor EL as a solubilizer, PEG 400 as a latent solvent, and mannitol as an excipient were mixed to increase the solubility of GB in water to more than 18 times (about from 2.5 × 10 −4 mol/L (0.106 mg/mL) to 1.914 mg/mL). Formulation screening was conducted by orthogonal design where the content of GB in the solution before lyophilization (using external standard method of HPLC) and reconstitution time after lyophilization were the two evaluation indexes. The optimized formulations were GB in an amount of 2 mg/mL, Cremophor EL in an amount of 16% (v/v), PEG 400 in an amount of 9% (v/v), mannitol in an amount of 8% (w/v), and the solution pH of 6.5. Through four single-factor experiments (GB adding order, preparation temperature of GB solution, adding amount, and adsorption time of activated carbon), the preparation process of GB solution was confirmed. The glass transition temperature of maximally GB freezeconcentrated solution was − 17.6°C through the electric resistance method. GB lyophilized powder began to collapse at − 14.0°C, and the fully collapsed temperature was − 13.0°C, which were determined by freeze-drying microscope. When the collapse temperature was determined, the primary drying temperature was obtained. Thereby, the freeze-drying curve of GB lyophilized powder was initially identified. The freeze-drying process was optimized by orthogonal design, the qualified product appearance and residual moisture content were the two evaluation indexes. The optimized process parameters and process were (1) shelf temperature, decreased from room temperature to − 45.0°C, at 0.5°C/min in 2 h; (2) shelf temperature increased from − 45.0 to − 25.0°C, at 0.1°C/min, maintained for 3 h, and the chamber pressure was held at 10 Pa; (3) shelf temperature was increased from − 25.0 to − 15.0°C at 0.1°C/min, maintained for 4 h, and the chamber pressure was held at 10 Pa; and (4) shelf temperature was increased from − 15.0 to 20.0°C at 1.0°C/min, maintained for 4 h, and the chamber pressure was raised up to 80 Pa. In these lyophilization process conditions, the products complied with relevant provisions of the lyophilized powders for injection. Meanwhile, the reproducibility was satisfactory. Post-freezing annealing had no significantly beneficial effects on shortening the freeze-drying cycle and improving the quality of GB lyophilized powder.
INTRODUCTION
Ginkgo biloba is among the oldest living trees, with a long history of use in traditional Chinese medicine. In recent years, the extracts of Ginkgo biloba leaf have been widely sold as herbal medications worldwide. The most unique components of the extracts are the terpene trilactones: ginkgolides and bilobalide. Ginkgolide B (GB) is one kind of the ginkgolides, and it is the most potent inhibitor of the platelet-activating factor receptor (PAFR) (1) . PAFR is a highly active mediator in the human body and has been implicated in various disease states (2) . GB has been postulated to include improvement of memory and increase blood circulation, as well as to have beneficial effects to sufferers of Alzheimer's disease (3, 4) and cisplatininduced ototoxicity (5) .
GB is a diterpene with a cage skeleton consisting of six 5-membered rings ( Fig.1 ): a spiro [4, 4] -nonane carbocyclic ring, three lactones, and a tetrahydrofuran ring, with a relative molecular weight of 424.4 g/mol (6) . GB is a white crystal and can be dissolved in acetone, ethanol, methanol, ethyl acetate, tetrahydrofuran, dioxane, acetic acid, trifluoroacetic acid, acetonitrile, pyridine, and dimethyl sulfoxide and can be slightly dissolved in ethyl ether and water (the solubility in water of 2.5 × 10 −4 mol/L (0.106 mg/mL)). GB cannot be dissolved in hexane, benzene, chloroform, and carbon tetrachloride (7, 8) . Under neutral or acidic conditions, all lactonic rings of GB are closed; under alkaline conditions (at pHs 7.5 to 12), some lactonic rings are opened because of hydrolysis. If the alkalinity increases, the majority of lactonic rings are opened to form salts. However, the GB without hydrolysis is the biologically active form. This is one of the reasons why some GB formulations cannot reach the expected clinical efficacy (9, 10) . Under physiological conditions, the lactonic rings of GB are partially hydrolyzed, the original form only accounts for 34% at equilibrium (11) .
G. biloba products are offered today in many different preparations, sometimes without any kind of scientific background and control. However, in evidence-based medicine and all clinical investigations and treatments, G. biloba should only be used in the form of standardized G. biloba extracts (e.g., EGb 761 ® , LI 1370 ® ) defined by a special composition and manufacturing process (12) . Since GB is poorly soluble in water and gastric fluid environment, resulting in low dissolution and bioavailability through oral administration, it limits the development of oral preparations to some extent (13) . Lyophilized formulations can be injected after reconstitution so that higher bioavailability can be ensured (14) . Furthermore, the loss of the active ingredient is reduced during the freeze-drying production. In general, lyophilized formulations are easy to transport and store long-term. In order to develop GB to lyophilized powder for injection, a five-step procedure has been carried out in this paper: (1) solvent, surfactant, excipient, and solution of PH screening for formulation; (2) process preparation of choosing GB API adding order, mixing temperature, added amount of active carbon, and absorption time; (3) freeze-drying optimization of process parameters for freeze stage, primary drying stage, and secondary drying stage; (4) verification experiments of lyophilization process; and (5) the effects of annealing on lyophilization rate and product quality.
MATERIALS AND METHODS

Materials
GB (the purity ≥ 98%) was purchased from Nanjing Dierge Medical and Technological Co., Ltd. (Jiangsu, China). Tween 80, Tween 20, Tween 40, Poloxamer 188, Cremophor El, glucose, lactose, mannitol, dextran20, sucrose, and Larginine were purchased from Aladdin Reagent Database Inc. (Shanghai, China), which were analytical grades. Methanol was obtained from Xingke Solvent Inc. (Shanghai, China), which was HPLC grade. Water for injection was supplied from GMP Training Center of China Pharmaceutical University.
Formulation Screening of GB Lyophilized Powder for Injection
Specification Determination. Only several G. biloba preparations were approved in China. On the basis of the G. biloba injection produced by Chengdu Baiyu Pharmaceutical Co., Ltd. (Sichuan, China), each vial contains 2 mL solution and 10 mg terpene lactones as active pharmaceutical ingredient (API) in which GB probably accounts for 34%, being equal to 1.7 mg/mL. Therefore, each vial contained 2 mL GB solution after reconstitution in this study, and the concentration of GB was 2.0 mg/mL.
Establishing a Standard Curve Between Concentrations and Peak Areas of GB. GB standards were accurately weighed and placed in a volumetric flask, then dissolved with methyl alcohol. The obtained solution was diluted by methyl alcohol to prepare standard solutions with different concentrations, such as 0.5 × 10 3 , 1 × 10 3 , 2 × 10 3 , 4 × 10 3 , and 6 × 10 3 mg/L, then the contents of GB were determined with HPLC (Shimadzu Co., Ltd., China). The chromatographic conditions were as follows: the column was Agilent ZORBAX SB-C18 (4.6 × 150 mm, 5 μm), the column temperature was 25°C, the mobile phase was methanolwater (50:50), the velocity of flow was 1.0 mL/min, the detection wavelength was 220 nm, and the injection volume was 20 μL.
The concentrations of GB and their correspondent peak area data are shown in Table I , the standard curve is shown in Fig. 2 . The results showed those from 0.5 × 10 3 to 6 × 10 3 mg/L, and three experiments were repeated at each concentration to get the standard deviation of the peak area. As a result, the linear relationship between concentrations and peak areas was good. The sampling precision test was done as follows: the reference solution (the concentration of 4 × 10 3 mg/L) was sampled six times, the peak areas were recorded, and RSD was 0.15% by calculation.
Solvent Selection. The most commonly used solvent in lyophilized powder for injection is water, but GB is poorly soluble in it. Therefore, mixed solvents were considered. Among solvents with the ability to dissolve GB, ethyl alcohol, propylene glycol, glycerin, PEG 200, and PEG 400 had higher safety, which could be mixed with water to form co-solvents. It was found that the solubility to GB of the co-solvents increased with their increased volume concentration. However, when volume concentrations of ethyl alcohol, propylene glycol, glycerin, and PEG 200 were above 10%, the frozen solid could easily spray during primary drying because their melting point were relatively low, which were hard to be fully frozen. Only PEG 400 had relatively high melting point, and the above phenomenon did not easily happen. So, PEG 400 and water for injection as the co-solvent was chosen.
Solubilization Method Selection. When poorly watersoluble drugs were prepared to lyophilized powders for injection, commonly solubilized methods included adding surfactants and latent solvents, adjusting pH, inclusion technique, emulsified or micro-emulsification, etc. When we design an experiment, in general, we should consider the operating conditions and procedure, the cost of experiment, the kind of equipment to be used, and the easiness to carry out the experiment. In this study, according to the physical and chemical properties of GB and the characteristics of lyophilized powders, adding surfactants and adjusting pH were chosen to increase the solubility of GB because these two methods are easy to fulfill, and efficient in cost. Only HPLC instrument is used for experiments; the other methods of increasing the solubility of GB will be discussed in the future. EL, etc. The concentrations of the above surfactants were mixed with 2 mg GB, respectively, then 1 mL water for injection was added, and ultrasonic processing was carried out for 10 min. Clarities of the obtained solution containing Poloxamer 188 or Cremophor EL were better than the others. It was found that molds produced easily in the Poloxamer 188 solution. So, the Cremophor EL was more suitable, and its safe dose was large (15) . GB was soluble and stable in concentrated acid but poorly soluble in weakly acid solution. In weakly alkaline solution, its lactone rings occurred in partial hydrolysis; with the increase of pH, more lactone rings opened. From the injection aspects to consider, it was suitable to adjust the pH of GB solution to be acidulous or neutral. The solution (which consisted of PEG 400, Cremophor EL, and water) pH value was around 6.0. Na 2 CO 3 , NaHCO 3 , phosphate, meglumine, L-arginine, etc. could be used as the basic pH-adjusting agents. L-Arginine played an important therapeutic effect on atherosclerosis, which could promote vasodilation and angiogenesis, as well as inhibit the aggregation of platelets and granulocytes (16) . Therefore, L-arginine was chosen as the pH-adjusting agent.
Excipient Screening. The desired appearance of lyophilized powder should be an intact and porous cake structure. Furthermore, the color should be uniform. In order to obtain a better appearance, some excipients were added into API to provide a lyophilized skeleton. The following five excipients were used in this experiment: glucose, lactose, mannitol, dextran 20, and sucrose. The above excipients were separately added in the PEG 400 and Cremophor EL solution, and the dosage of each excipient was 6% (g/mL). Then, solution appearance and lyophilized product appearances of above obtained solutions were compared, and the results are shown in Fig. 3 and Table II . By comprehensive comparison, mannitol as the excipient was the best because the structure by mannitol as excipient is intact and porous, which means there is no defect (no collapse, no crack on the surface, no shrink, no spray phenomenon, and no collapse at the bottom).
Formulation Screening by Orthogonal Design. After the determination of solubilization methods and excipients, the formulation of GB lyophilized powder for injection was screened by orthogonal design. The following four items were used as investigation factors: (a) PEG 400 concentration (mL/mL), (b) Cremophor EL concentration (mL/mL), (c) mannitol concentration (g/mL), and (d) solution pH. GB content in the prepared solution before freeze-drying and its reconstitution time after freeze-drying were used as two evaluation indexes. The GB content was determined through external standard method of HPLC, building a L 9 (3 4 ) orthogonal table.
Freeze-Drying Process Optimization of GB Lyophilized Powder for Injection
Determination of Glass Transition Temperature of Maximally Freeze-Concentrated Solution
In the freeze-drying process, three stages are included. They are freezing, primary drying, and secondary drying. In the freezing stage, the lowest temperature could be confirmed on the basis of freezing point (including eutectic temperature or glass transition temperature), and the highest temperature during the primary drying was confirmed on the basis of collapse temperature. Material freezing point is usually determined through electric resistance method, freeze-drying microscope observation method, and differential scanning calorimetry (17) .
According to the optimized formulation, the GB solution was prepared and the vials with GB solution were placed on the shelves of the freeze drier (Shanghai Tofflon Co., Ltd., China). Two electrodes of the digital multi-meter were fixed on both sides in a beaker, and the solution temperature was determined by temperature probes of the freeze drier. Electric resistances of GB solution and corresponding temperatures were recorded as shown in Table III . Then the temperature-resistance curve was obtained from data directly and from data by regression (shown in Fig. 4) ; the temperature at the maximum curvature was the freezing point. The (18):
where k is the slope of temperature-resistance curve, R is the solution resistance (MΩ), R′ is the first derivative of the solution resistance, R″ is the second derivative, and T is the solution temperature (°C). There was not a fixed melting point of GB solution by DSC 204 F1 (Netzsch Geraetebau GmbH, Germany). Therefore, where the freezing point was the glass transition temperature of maximally GB freeze-concentrated solution (Tg′). By calculation, the freezing point of GB solution was − 17.6°C, while the freezing point was determined at − 16.5°C through freeze-drying microscope observation method. We can see that the glass transition temperature measured by two method has a 1°C difference; it proves that the measured transition temperature has a high accuracy. In general case, the lowest temperature during the freezing was about 10~20°C lower than Tg′. Therefore, the lowest freezing temperature was at − 45.0°C to ensure the material being fully frozen.
Determination of Collapse Temperature
During primary drying, if the product temperature is higher than the collapse temperature, the amorphous material will undergo viscous flow, resulting in loss of the pore structure obtained by freezing, which is defined as the collapse phenomenon by Pikal and Shah (19) . Collapsed dried products generally have a high residual water content and lengthy reconstitution times and may also present a loss of functional properties. Moreover, in the pharmaceutical industry, collapse is normally a cause for rejection of the vials due to the lack of material elegance. Since a small variation of temperature can greatly modify the primary drying time as well as the dried product structure, an accurate determination of the collapse temperature is critical for the process optimization (20) ; the freeze-dry microscope usually is used for measuring collapse temperature.
Collapse temperature of GB lyophilized powder for injection was determined by the FDCS 196 freeze-drying microscope (Linkam Scientific Instruments Ltd., UK). GB solution (2 μL) was taken and dropped between two glass cover slips. Then the freeze-drying stage was sealed, and an appropriate multiple objective was used to observe the solution. The solution was cooled from room temperature to − 45.0°C at 10.0°C/min, then the freeze-drying stage was moved to find the edge of the frozen solution, and the pressure in the stage was maintained at about 20 Pa. Slow heating followed; the movement of sublimation interface was observed to judge at what temperature it began to collapse and collapsed completely, respectively. During − 45.0 to − 15.0°C, the sublimation interface moved from the edge of the glass slide to the center; there was a very clear sublimation interface between the drying zone and the freeze zone. And at − 14.0°C, the sublimation interface became not clear and there was a small quantity of viscous flow, resulting in loss of the pore structure, meaning − 14.0°C was the temperature of the onset of collapse. When the temperature increased to − 13.0°C, the more viscous flow happened near the sublimation interface, judging that − 13.0°C was the full collapse temperature. Heating up continually, much more viscous flow happened, and all are shown in Fig. 5 . Hence, the highest temperature of primary drying was below − 14.0°C.
Optimization of the Freeze-Drying Process by Orthogonal Design
Firstly, various factors influencing GB lyophilized powder quality were confirmed from preliminary experiments, then freeze-drying process was optimized by orthogonal design. The following four items were used as investigation factors: I: freezing temperature, cooling rate, and duration; II: temperature changes during the primary drying, with gradient heating at 0.1°C/min; III: the primary drying time and pressure; and IV: the secondary drying temperature and pressure. Appearance yield and residual water content were as two evaluation indexes, building a L 9 (3 4 ) orthogonal table. Residual water content was determined by V 20 Karl Fischer (METTLER TOLEDO, Switzerland). Qualified appearance criterions were that it should be an intact and porous cake structure (no collapse, no crack on the surface, no shrink, no spray phenomenon, no collapse at the bottom, etc.), without significant volume changes before and after lyophilization (21) .
RESULTS AND DISCUSSIONS
Optimized Formulation
The formulation was optimized by an orthogonal design using the software SPSS 19.0. Factor levels are shown in Table IV , orthogonal results are shown in Table V Note: If F ratio > F critical value, P < 0.01, representing the difference was significant. The effect of C (mannitol concentration) on GB content could be neglected, and its range value in Table V was minimum, so the factor C was chosen as error term the intuitively ranged analysis of GB content and reconstitution time in Table V , the range values represented the influence order of the factors. Therefore, according to the range values in Table V Table VI , through the variance analysis of GB content, only factor D had a significant influence (p < 0.01), obtaining the highest GB content when factor D in level 1 in Table V (the GB content Table VII , factor A, B, and D had significant effects on GB lyophilized powder reconstitution time. And in Table V , when factor A and B were in level 3, the reconstitution time was the shortest. On both GB content and reconstitution time respects by the variance analyses in Tables VI and VII, factor C had no significant effect on measurements. But the amount of mannitol was chosen 8% (g/mL), as the obtained GB lyophilized powder was the most intact and porous by comparing 6% (g/mL) and 10% (g/mL). Through comprehensive analyses of the two evaluation indexes, the optimized formulation was D 1 B 3 A 3 C 2 , i.e., pH at 6.5, Cremophor EL in an amount of 16% (mL/mL), PEG 400 in an amount of 9% (mL/mL), and mannitol in an amount of 8% (g/mL).
Confirmation of GB Solution Preparation Process
GB stability is affected by GB adding order, preparing GB solution temperature, amount of activated carbon, and its adsorption time experiments. For example, the order of adding GB API will affect the transparent time of mixed solution; high temperature of preparing GB solution will cause the GB to decompose; the over amount of active carbon added and more adsorption time of active carbon will cause the GB content decrease. So, GB adding order, preparing GB solution temperature, amount of activated carbon, and its adsorption time experiments were set up one factor at a time to study their effects on GB stability. GB solution preparation process was confirmed as follows: 2.0 mg/mL GB was taken and added into the mixed solvent of 16% (mL/mL) Cremophor El and 9% (mL/ mL) PEG 400, via ultrasonic treatment for 10 min. Then prescribed water for injection were added in it under electromagnetic stirring, and 8% (g/mL) mannitol was added to the obtained solution; L-arginine was used to adjust the pH at 6.5. And 0.05% (g/mL) activated carbon was added into the above solution, then under electromagnetic stirring (1000 r/min) for 35 min at 40.0°C, which was filtered through 0.22-μm PVDF membrane, finally filled, and freeze-dried.
Optimized Freeze-Drying Parameters
Through above, freeze-drying parameter optimization was carried out with SPSS 19.0 using an orthogonal design. Factor levels are shown in Table VIII, orthogonal design results are  shown in Table IX , and variance analysis results are shown in Tables X and XI. For the intuitively ranged analysis of appearance yield and residual water in Table IX , the range values represented the influence order of factors. According to Note: If F ratio > F critical value, P < 0.01, representing the difference was significant. The effect of C (mannitol concentration) on reconstitution time could be neglected, and its range value in Table V was minimum, so the factor C was chosen as error term Table VIII . Table IX , considering the appearance yields, the influence order of the factors was I > II > III > IV (I: freezing temperature, cooling rate, and duration; II: temperature changes during the primary drying, with gradient heating at 0.1°C/min; III: the primary drying time and pressure; IV: the secondary drying temperature and pressure). As for the evaluation index of appearance yield, the higher mean value under one factor (I, II, III, IV) was required, so I 1 II 3 III 1 IV 1 was chosen as the optimized freeze-drying parameters. Similarly, for the residual water content, the order of the factors was II > IV > I > III. Since the lower residual water content of GB lyophilized powder the better, II 3 IV 3 I 1 III 3 was chosen as the optimized freeze-drying parameters.
As shown in Table X , through the variance analysis of appearance yields, the factors I and II had significant effects (P value < 0.05). And in Table IX , when factor I was in level 1 and factor II in level 3, the appearance yield was the highest. As shown in Table XI , factors II and IV had significant effects on the residual water content. When factor II was in level 3 and factor IV in level 3, the residual water content of GB lyophilized powder was the lowest. On both appearance yield and residual water content respects, factor III had no significant effects. In fact, it is well known that shorter drying time can shorten the whole freeze-drying cycle and improve the productivity for enterprises, so III 1 (12 h, 10 Pa) was chosen as the duration of primary drying. Based on the above considerations, I 1 II 3 III 1 IV 3 was the optimized freeze-drying parameters.
Verification of Lyophilization Process
According to the previously optimized process, three batches of 300 mL GB solution were prepared and filled into 7-mL vials, and each vial contained 2 mL solution. These 100 vials were lyophilized in accordance with the optimized freezedrying parameters, with the freeze-drying cycle of 20.7 h. All products were intact and porous, the mean reconstitution time was 41 ± 5 s, and the mean residual water content was 1.18 ± 0.14%. It showed that the optimized formulation and freeze-drying process could meet the specifications of lyophilized powder for injection, and with a good reproducibility.
Effects of Annealing on Lyophilization Rate and Product Quality
Some researches reported that annealing could improve lyophilization rate and shorten the freeze-drying cycle (22, 23) . Hence, experiments were carried out to study the effects of Note: If F ratio > F critical value, P < 0.01, representing the difference was significant. The range value of factor IV in Table IX on appearance yields was minimum, so it was chosen as error term annealing on lyophilization rate and product quality. The frozen solution was heated to above the eutectic temperature or glass transition temperature, but below the melting temperature, held for a specified duration and then frozen again. In the experiments, GB solution has a glass transition temperature of − 17.6°C, so the annealing temperature was set as two different temperatures of − 14.5 and − 8.0°C.
Annealing at − 14.5°C
At normal atmospheric pressure, the GB solution was frozen from room temperature to − 45.0°C, and then immediately heated to −14.5°C. This temperature was maintained constant for 1 h, so that the lyophilization process continued following the abovementioned optimized freeze-drying parameters. By annealing at − 14.5°C, the period of primary drying was shortened to about 3 h, so that the whole cycle was 21.7-h long. Compared to the GB lyophilized powder without annealing, the products annealed at − 14.5°C were looser, and the apertures were larger, even showing some cavities, and slight collapse occurred for about 1% of the material, as shown in Fig. 6 . In terms of residual water content, GB content, related substances, and pH, both of the two had no significant differences.
Annealing at − 8.0°C
Like the above annealing treatment, another batch of GB solution was annealed at − 8.0°C for 1 h. The period of primary drying was shortened to about 3 h, the freeze-drying cycle was 22.2 h, and the whole process parameters was automatically recorded by the lyophilizer. GB lyophilized powder in all vials shrunk severely and had difficult reconstitution, shown in Fig. 7 . Compared to the GB lyophilized powder without annealing, the products annealed at − 14.5°C had no significant differences in terms of residual water content, GB content, related substances, and pH.
To find the reason of annealing collapse at − 14.5 and − 8.0°C, decreasing freeze temperature and extending its time, decreasing the highest temperature and pressure of the primary drying measures were taken; only decreasing the highest temperature of the primary drying was helpful to improve the collapse. It could be deduced that the annealing treatment might improve the collapse temperature because of the changes of ice crystal morphology and size distribution. Thus, qualified GB lyophilized powder for injection could be obtained according to the optimized process, without annealing.
CONCLUSION
In this paper, the optimal formulation of GB lyophilized powder for injection was determined alongside the optimized conditions for the complete formulation process. Firstly, solvent, solubilizer, excipient, and pH were screened, PEG 400 in an amount of 9% (mL/mL), Cremophor EL in an amount of 16% (mL/mL), mannitol in an amount of 8% (g/mL), and pH at 6.5 were determined to make the solubility of GB improve to more than 18 times (from 0.106 to 1.914 mg/mL). Secondly, the preparing process was carried out by using a one factor at a time experimental design; Note: If F ratio > F critical value, P < 0.01, representing the difference was significant. The range value of factor III in Table IX on residual water content was minimum, so it was chosen as error term Fig. 6 . The left vial is the appearance of GB lyophilized powder without annealing, having a loose and porous structure; the right vial with annealing at − 14.5°C. The apertures were larger, even existing some cavities between upper and lower surface Fig. 7 . The left vial is the appearance of GB lyophlized powder without annealing, having a loose and porous structure; the right vial with annealing at − 8.0°C. GB lyophilized powder solid shrinked up severely and separated from the bottom completely thirdly, by orthogonal design, the optimized formulation was obtained. The optimized operation schedule for the process was freezing from room temperature to − 45.0°C at 0.5°C/ min, then holding for 2 h; in the primary drying stage, heating the temperature from − 45.0 to − 25.0°C at 0.1°C/min, and then holding for 3 h; heating the temperature from − 25.0 to − 15.0°C at 0.1°C/min, and holding for 4 h. In the whole primary drying stage, the chamber pressure was kept at 10 Pa; in the secondary drying stage, heating the temperature from − 15.0 to 20.0°C at 1°C/min, and holding for 4 h, with the chamber pressure kept to 80 Pa. Then, the verification batch experiments have been carried out according to the above optimized protocol. A very satisfactory quality for GB lyophilized power for injection was achieved. Furthermore, post-freezing annealing process analysis has been carried out. The relevant discovery was that annealing is not beneficial for the process since it did not allow to reduce the freeze-drying cycle and, what was worse, it caused some collapse on the material. Therefore, a complete process of formulation preparation of GB lyopilized power for injection has been given. This study would provide references for optimization technology of GB lyophilized powder for injection.
